An online tool developed to facilitate efficient patient-provider decisions on disease modifying drugs for multiple sclerosis (MS) ran into several challenges and warrants further study. Researchers ...
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis There is a need for industry-independent decision tools that integrate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback